Diabetology International

, Volume 5, Issue 3, pp 175–180

Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia

  • Motoya Koie
  • Yasushi Kondo
  • Tomohiro Santou
  • Yuka Kitamoto
  • Sei Morita
  • Masayuki Yamasaki
  • Mitsuo Fukushima
  • Nobuya Inagaki
  • Koichiro Yasuda
Original Article

DOI: 10.1007/s13340-013-0152-9

Cite this article as:
Koie, M., Kondo, Y., Santou, T. et al. Diabetol Int (2014) 5: 175. doi:10.1007/s13340-013-0152-9

Abstract

Introduction

Type 2 diabetes is a risk factor for atherosclerosis because concomitant hypercholesterolemia further exacerbates hyperglycemia. We compared the efficacy of non-statin and non-fibrate antilipemic drugs in type 2 diabetes patients with hypercholesterolemia, and evaluated the flow-mediated vasodilation (FMD), a marker of early atherosclerotic changes.

Patients and methods

Fifty outpatients (aged 39–79) with type 2 diabetes and low-density lipoprotein cholesterol levels of ≥120 mg/dl were randomly allocated into two groups: 23 patients first received ezetimibe for 4 months followed by eicosapentaenoic acid (EPA) for the next 4 months, and 27 patients first received eicosapentaenoic acid for 4 months followed by ezetimibe for the next 4 months. Glycated hemoglobin and serum lipid levels were measured before and 4 and 8 months after treatment. Ankle brachial pressure index, intimal medial thickness, and FMD were measured in 35 patients. A pretreatment group (group 0) was added. We compared data from groups 0, A (subjects receiving ezetimibe), and B (subjects receiving EPA) during and after treatment.

Results

Non-high-density lipoprotein cholesterol levels decreased significantly in group A compared with groups 0 and B. No significant difference in serum high-density lipoprotein cholesterol levels was observed among the groups, whereas triglyceride levels decreased significantly in group B compared with group 0. FMD increased significantly in groups A and B compared with group 0.

Conclusion

FMD investigation may affect the evaluation of early atherosclerotic changes, and the administration of ezetimibe and EPA may be useful for patients with type 2 diabetes with hypercholesterolemia because it improves vascular endothelial function.

Keywords

Flow-mediated vasodilationEicosapentaenoic acidEzetimibeAtherosclerosisHypercholesterolemia

Copyright information

© The Japan Diabetes Society 2013

Authors and Affiliations

  • Motoya Koie
    • 1
  • Yasushi Kondo
    • 1
    • 2
  • Tomohiro Santou
    • 1
  • Yuka Kitamoto
    • 1
  • Sei Morita
    • 1
  • Masayuki Yamasaki
    • 3
  • Mitsuo Fukushima
    • 4
  • Nobuya Inagaki
    • 2
  • Koichiro Yasuda
    • 1
  1. 1.Department of Diabetology and EndocrinologyOsaka Saiseikai Noe HospitalOsakaJapan
  2. 2.Department of Diabetes, Endocrinology and Nutrition, Graduate School of MedicineKyoto UniversityKyotoJapan
  3. 3.Department of Clinical ExaminationOsaka Saiseikai Noe HospitalOsakaJapan
  4. 4.Department of Nutrition Science, Faculty of Health and Welfare ScienceOkayama Prefectural UniversityOkayamaJapan